Modulation of breast cancer risk biomarkers by high-dose omega-3 fatty acids: Phase II pilot study in premenopausal women

Carol J. Fabian, Bruce F. Kimler, Teresa A. Phillips, Jessica A. Box, Amy L. Kreutzjans, Susan E. Carlson, Brandon H. Hidaka, Trina Metheny, Carola M. Zalles, Gordon Mills, Kandy R. Powers, Debra K. Sullivan, Brian K. Petroff, Whitney L. Hensing, Brooke L. Fridley, Stephen D. Hursting

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Higher intakes of the omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to the omega-6 arachidonic acid (AA) have been variably associated with reduced risk of premenopausal breast cancer. The purpose of this pilot trial was to assess feasibility and explore the effects of high-dose EPA and DHA on blood and benign breast tissue risk biomarkers before design of a placebo-controlled phase IIB trial. Premenopausal women with evidence of hyperplasia-Atypia by baseline random periareolar fine needle aspiration were given 1860 mg of EPA + 1500mgofDHAethyl esters daily for 6 months. Blood and benign breast tissue were sampled during the same menstrual cycle phase prestudy and a median of 3 weeks after last dose. Additional blood was obtained within 24 hours of last dose. Feasibility, which was predefined as 50% uptake, 85% retention, and 70% compliance, was demonstrated with 46% uptake, 94% completion, and 85% compliance. Cytologic atypia decreased from 77% to 38% (P = 0.002), and Ki-67 from a median of 2.1% to 1.0% (P = 0.021) with an increase in the ratio of EPA + DHA to AA in erythrocyte phospholipids but no change in blood hormones, adipokines, or cytokines. Exploratory breast proteomics assessment showed decreases in several proteins involved in hormone and cytokine signaling with mixed effects on those in the AKT/ mTORpathways. Further investigation of EPA plusDHAfor breast cancer prevention in a placebo-controlled trial in premenopausal women is warranted.

Original languageEnglish (US)
Pages (from-to)912-921
Number of pages10
JournalCancer Prevention Research
Volume8
Issue number10
DOIs
StatePublished - Oct 1 2015
Externally publishedYes

Fingerprint

Eicosapentaenoic Acid
Omega-3 Fatty Acids
Tumor Biomarkers
Docosahexaenoic Acids
Breast Neoplasms
Breast
Arachidonic Acid
Compliance
Placebos
Hormones
Cytokines
Adipokines
Menstrual Cycle
Fine Needle Biopsy
Proteomics
Hyperplasia
Phospholipids
Esters
Erythrocytes
Biomarkers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Fabian, C. J., Kimler, B. F., Phillips, T. A., Box, J. A., Kreutzjans, A. L., Carlson, S. E., ... Hursting, S. D. (2015). Modulation of breast cancer risk biomarkers by high-dose omega-3 fatty acids: Phase II pilot study in premenopausal women. Cancer Prevention Research, 8(10), 912-921. https://doi.org/10.1158/1940-6207.CAPR-14-0335

Modulation of breast cancer risk biomarkers by high-dose omega-3 fatty acids : Phase II pilot study in premenopausal women. / Fabian, Carol J.; Kimler, Bruce F.; Phillips, Teresa A.; Box, Jessica A.; Kreutzjans, Amy L.; Carlson, Susan E.; Hidaka, Brandon H.; Metheny, Trina; Zalles, Carola M.; Mills, Gordon; Powers, Kandy R.; Sullivan, Debra K.; Petroff, Brian K.; Hensing, Whitney L.; Fridley, Brooke L.; Hursting, Stephen D.

In: Cancer Prevention Research, Vol. 8, No. 10, 01.10.2015, p. 912-921.

Research output: Contribution to journalArticle

Fabian, CJ, Kimler, BF, Phillips, TA, Box, JA, Kreutzjans, AL, Carlson, SE, Hidaka, BH, Metheny, T, Zalles, CM, Mills, G, Powers, KR, Sullivan, DK, Petroff, BK, Hensing, WL, Fridley, BL & Hursting, SD 2015, 'Modulation of breast cancer risk biomarkers by high-dose omega-3 fatty acids: Phase II pilot study in premenopausal women', Cancer Prevention Research, vol. 8, no. 10, pp. 912-921. https://doi.org/10.1158/1940-6207.CAPR-14-0335
Fabian, Carol J. ; Kimler, Bruce F. ; Phillips, Teresa A. ; Box, Jessica A. ; Kreutzjans, Amy L. ; Carlson, Susan E. ; Hidaka, Brandon H. ; Metheny, Trina ; Zalles, Carola M. ; Mills, Gordon ; Powers, Kandy R. ; Sullivan, Debra K. ; Petroff, Brian K. ; Hensing, Whitney L. ; Fridley, Brooke L. ; Hursting, Stephen D. / Modulation of breast cancer risk biomarkers by high-dose omega-3 fatty acids : Phase II pilot study in premenopausal women. In: Cancer Prevention Research. 2015 ; Vol. 8, No. 10. pp. 912-921.
@article{39bcba76c11c4c4c80e8bbd02f3067c6,
title = "Modulation of breast cancer risk biomarkers by high-dose omega-3 fatty acids: Phase II pilot study in premenopausal women",
abstract = "Higher intakes of the omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to the omega-6 arachidonic acid (AA) have been variably associated with reduced risk of premenopausal breast cancer. The purpose of this pilot trial was to assess feasibility and explore the effects of high-dose EPA and DHA on blood and benign breast tissue risk biomarkers before design of a placebo-controlled phase IIB trial. Premenopausal women with evidence of hyperplasia-Atypia by baseline random periareolar fine needle aspiration were given 1860 mg of EPA + 1500mgofDHAethyl esters daily for 6 months. Blood and benign breast tissue were sampled during the same menstrual cycle phase prestudy and a median of 3 weeks after last dose. Additional blood was obtained within 24 hours of last dose. Feasibility, which was predefined as 50{\%} uptake, 85{\%} retention, and 70{\%} compliance, was demonstrated with 46{\%} uptake, 94{\%} completion, and 85{\%} compliance. Cytologic atypia decreased from 77{\%} to 38{\%} (P = 0.002), and Ki-67 from a median of 2.1{\%} to 1.0{\%} (P = 0.021) with an increase in the ratio of EPA + DHA to AA in erythrocyte phospholipids but no change in blood hormones, adipokines, or cytokines. Exploratory breast proteomics assessment showed decreases in several proteins involved in hormone and cytokine signaling with mixed effects on those in the AKT/ mTORpathways. Further investigation of EPA plusDHAfor breast cancer prevention in a placebo-controlled trial in premenopausal women is warranted.",
author = "Fabian, {Carol J.} and Kimler, {Bruce F.} and Phillips, {Teresa A.} and Box, {Jessica A.} and Kreutzjans, {Amy L.} and Carlson, {Susan E.} and Hidaka, {Brandon H.} and Trina Metheny and Zalles, {Carola M.} and Gordon Mills and Powers, {Kandy R.} and Sullivan, {Debra K.} and Petroff, {Brian K.} and Hensing, {Whitney L.} and Fridley, {Brooke L.} and Hursting, {Stephen D.}",
year = "2015",
month = "10",
day = "1",
doi = "10.1158/1940-6207.CAPR-14-0335",
language = "English (US)",
volume = "8",
pages = "912--921",
journal = "Cancer Prevention Research",
issn = "1940-6207",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Modulation of breast cancer risk biomarkers by high-dose omega-3 fatty acids

T2 - Phase II pilot study in premenopausal women

AU - Fabian, Carol J.

AU - Kimler, Bruce F.

AU - Phillips, Teresa A.

AU - Box, Jessica A.

AU - Kreutzjans, Amy L.

AU - Carlson, Susan E.

AU - Hidaka, Brandon H.

AU - Metheny, Trina

AU - Zalles, Carola M.

AU - Mills, Gordon

AU - Powers, Kandy R.

AU - Sullivan, Debra K.

AU - Petroff, Brian K.

AU - Hensing, Whitney L.

AU - Fridley, Brooke L.

AU - Hursting, Stephen D.

PY - 2015/10/1

Y1 - 2015/10/1

N2 - Higher intakes of the omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to the omega-6 arachidonic acid (AA) have been variably associated with reduced risk of premenopausal breast cancer. The purpose of this pilot trial was to assess feasibility and explore the effects of high-dose EPA and DHA on blood and benign breast tissue risk biomarkers before design of a placebo-controlled phase IIB trial. Premenopausal women with evidence of hyperplasia-Atypia by baseline random periareolar fine needle aspiration were given 1860 mg of EPA + 1500mgofDHAethyl esters daily for 6 months. Blood and benign breast tissue were sampled during the same menstrual cycle phase prestudy and a median of 3 weeks after last dose. Additional blood was obtained within 24 hours of last dose. Feasibility, which was predefined as 50% uptake, 85% retention, and 70% compliance, was demonstrated with 46% uptake, 94% completion, and 85% compliance. Cytologic atypia decreased from 77% to 38% (P = 0.002), and Ki-67 from a median of 2.1% to 1.0% (P = 0.021) with an increase in the ratio of EPA + DHA to AA in erythrocyte phospholipids but no change in blood hormones, adipokines, or cytokines. Exploratory breast proteomics assessment showed decreases in several proteins involved in hormone and cytokine signaling with mixed effects on those in the AKT/ mTORpathways. Further investigation of EPA plusDHAfor breast cancer prevention in a placebo-controlled trial in premenopausal women is warranted.

AB - Higher intakes of the omega-3 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) relative to the omega-6 arachidonic acid (AA) have been variably associated with reduced risk of premenopausal breast cancer. The purpose of this pilot trial was to assess feasibility and explore the effects of high-dose EPA and DHA on blood and benign breast tissue risk biomarkers before design of a placebo-controlled phase IIB trial. Premenopausal women with evidence of hyperplasia-Atypia by baseline random periareolar fine needle aspiration were given 1860 mg of EPA + 1500mgofDHAethyl esters daily for 6 months. Blood and benign breast tissue were sampled during the same menstrual cycle phase prestudy and a median of 3 weeks after last dose. Additional blood was obtained within 24 hours of last dose. Feasibility, which was predefined as 50% uptake, 85% retention, and 70% compliance, was demonstrated with 46% uptake, 94% completion, and 85% compliance. Cytologic atypia decreased from 77% to 38% (P = 0.002), and Ki-67 from a median of 2.1% to 1.0% (P = 0.021) with an increase in the ratio of EPA + DHA to AA in erythrocyte phospholipids but no change in blood hormones, adipokines, or cytokines. Exploratory breast proteomics assessment showed decreases in several proteins involved in hormone and cytokine signaling with mixed effects on those in the AKT/ mTORpathways. Further investigation of EPA plusDHAfor breast cancer prevention in a placebo-controlled trial in premenopausal women is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84943226327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84943226327&partnerID=8YFLogxK

U2 - 10.1158/1940-6207.CAPR-14-0335

DO - 10.1158/1940-6207.CAPR-14-0335

M3 - Article

C2 - 26438592

AN - SCOPUS:84943226327

VL - 8

SP - 912

EP - 921

JO - Cancer Prevention Research

JF - Cancer Prevention Research

SN - 1940-6207

IS - 10

ER -